Camp4 Therapeutics (CAMP) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on regulatory RNA-based therapeutics to upregulate gene expression for genetic diseases.

• Proprietary RNA Actuating Platform (RAP Platform) enables identification and targeting of regulatory RNAs (regRNAs) to modulate gene expression.

• Lead programs target metabolic and CNS disorders, with initial focus on urea cycle disorders (UCDs) and SYNGAP1-related disorders.

• Retains exclusive, worldwide development and commercialization rights to all product candidates and discovery programs.

Financial performance and metrics

• Reported net losses of $49.3M in 2023 and $44.2M in 2022; net loss of $25.0M for the six months ended June 30, 2024.

• Accumulated deficit of $185.0M as of June 30, 2024.

• Cash and cash equivalents of $12.6M as of June 30, 2024; working capital of $8.6M.

• No product revenue to date; revenue from collaboration and license agreements totaled $0.35M in 2023.

• Auditor expressed substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from IPO, together with existing cash, intended to fund: (i) clinical development of CMP-CPS-001 for UCDs, (ii) advancement of CMP-SYNGAP for SYNGAP1-related disorders, (iii) expansion of RAP Platform and preclinical programs, and (iv) working capital and general corporate purposes.

• Proceeds may also be used for in-licensing, acquisitions, or investments in products, technologies, or businesses.